Table 3.

Response and survival

	Best response in brain#					Median survival
	CR	PR	mPR	SD	PD	months (range)
Study population (n = 24)*	0	4 (17%)	5 (21%)	5 (21%)	8 (33%)	5 (1.5–17)
Bortezomib dose group
(mg/m2/dose)
0.9 (n = 5)	0	1 (20%)	0	1 (20%)	3 (60%)	7 (5–11)
1.1 (n = 4)	0	2 (50%)	1 (25%)	1 (25%)	0	5.8 (2.5–7)
1.3 (n = 4)	0	0	3 (75%)	0	1 (25%)	9.5 (5–12.5)
1.5 (n = 2)	0	0	0	0	2 (100%)	11 (5–17)
1.7 (n = 9)¶	0	1 (11%)	1 (11%)	3 (33%)	2 (22%)	4 (1–8)
Radiation dose
30 Gy (3 Gy fractions)	0	4 (100%)	4 (100%)	2 (25%)	7 (87.5%)	7 (1.5–17)
37.5 Gy (2.5 Gy fractions)†	0	0 (0%)	0	3 (75%)	1 (12.5%)	4 (1.5–8)

^* Pre- and post- treatment brain MRI or CT with contrast available on 22 patients.

^# CR: complete response; PR: partial response; mPR: minor response; SD: stable disease; PD: progressive disease.

^¶ Pre- and post-treatment brain MRI or CT with contrast available on 7 of 9 patients. Survival data available on all patients.

^† Pre- and post-treatment brain MRI or CT with contrast available on 4 of 5 patients treated with 37.5 Gy.